3rd RSC / SCI Symposium on Antimicrobial Drug Discovery
3rd RSC / SCI symposium on antimicrobial drug discovery
Monday-Tuesday, 15th-16th November 2021
SCI, 14/15 Belgrave Square, London, SW1X 8PS, UK
Downloads and Links
At a time when antimicrobial resistance is decreasing the efficacy of existing treatments, it has never been more important that we refresh the drug pipeline with new therapeutics acting on new targets or exhibiting novel modes of action.
Fortunately, renewed interest from both industry and academia has led to a resurgence in antimicrobial drug discovery and interest in developing innovative technologies and approaches for combating infection.
Coinciding with WHO’s World Antibiotics Awareness week, this two-day meeting will examine the latest advances in antimicrobial drug discovery from a medicinal chemist’s perspective, focusing on the particular challenges associated with developing antimicrobials whilst also showcasing emerging strategies for tackling infection.
Who should attend
Bringing together leading exponents in the field from industry and academia, the meeting will appeal to anyone with an interest in antimicrobial resistance and antimicrobial drug discovery. And with great opportunities for academic–industrial partnerships, researchers from both sectors will also benefit from the networking opportunities that the meeting will offer.
Call for Posters and Flash Presentations
Anyone wishing to present a poster should submit a one-page abstract to email@example.com by Friday 10 September 2021 with “AM-III – poster abstract” in the subject line. Selected poster presenters will have the opportunity to give a flash presentation.
Addressing unusual anti-infective targets
Anna Hirsch, Helmholtz Institute of Pharmaceutical Research, Saarland, Germany
Discovery of ETX0462, a novel non-beta-lactam PBP inhibitor to treat Gram-negative infections, including MDR Pseudomonas aeruginosa
Thomas Durand-Reville, Entasis Therapeutics, MA, USA
The truth is out there: Nature as a source of new antimicrobials and alternatives
Gerry Wright, McMaster University, Canada
Tethered macrocyclic peptides, a novel antibiotic class targeting Acinetobacter baumannii
Patrizio Mattei, McMaster University, Canada
More speakers will be announced in due course.
Registration is not yet open.
Details to be provided.
Sponsors are encouraged to support this event, and we are grateful to our confirmed sponsors: MedChemica.
Dr Liam Cox, University of Birmingham
Dr Caroline Low, Computational Medicinal Chemistry Consultant
Dr Pascal Savy, Charles River Laboratories
Dr Francis Wilson, Summit Therapeutics
Secretariat Contact and Further Information
SCI Conference Team
Tel: +44 (0)20 7598 15611